LSINCT5

Summary

LSINCT5 (long stress-induced non-coding transcript 5, HGNC:37824) is a long non-coding RNA gene on chromosome 5p15.33.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:37824
Approved symbol	LSINCT5
Name	long stress-induced non-coding transcript 5
Location	5p15.33
Locus type	RNA, long non-coding
Status	Approved
Ensembl gene	ENSG00000281560
Ensembl biotype	lncRNA
OMIM	615764
Entrez	101234261
RNAcentral	URS000020D25D — lncRNA, 2647 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 lncRNA

ENST00000626215

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000626215 — 1 exons

Exon	Start	End
ENSE00003773368	2712591	2715237

Expression profiles

Bgee: expression breadth broad, 34 present calls, max score 57.88.

Top tissues by expression

34 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
minor salivary gland	UBERON:0001830	57.88	gold quality
saliva-secreting gland	UBERON:0001044	57.80	gold quality
blood	UBERON:0000178	53.74	gold quality
thoracic mammary gland	UBERON:0005200	48.42	gold quality
heart left ventricle	UBERON:0002084	46.76	silver quality
islet of Langerhans	UBERON:0000006	46.72	gold quality
fundus of stomach	UBERON:0001160	46.71	gold quality
heart	UBERON:0000948	45.89	silver quality
body of stomach	UBERON:0001161	44.93	gold quality
zone of skin	UBERON:0000014	43.91	silver quality
skin of abdomen	UBERON:0001416	43.90	silver quality
skin of leg	UBERON:0001511	43.84	silver quality
right lung	UBERON:0002167	43.73	silver quality
placenta	UBERON:0001987	43.17	silver quality
lung	UBERON:0002048	42.29	silver quality
metanephros cortex	UBERON:0010533	41.97	silver quality
esophagogastric junction muscularis propria	UBERON:0035841	41.56	silver quality
gastrocnemius	UBERON:0001388	41.53	silver quality
tibial artery	UBERON:0007610	41.47	silver quality
tibial nerve	UBERON:0001323	41.44	gold quality
upper lobe of left lung	UBERON:0008952	41.15	silver quality
subcutaneous adipose tissue	UBERON:0002190	40.70	silver quality
colon	UBERON:0001155	40.69	silver quality
Ammon’s horn	UBERON:0001954	40.41	silver quality
lower esophagus muscularis layer	UBERON:0035833	40.26	silver quality
esophagus mucosa	UBERON:0002469	40.14	silver quality
adult mammalian kidney	UBERON:0000082	39.77	silver quality
prostate gland	UBERON:0002367	38.87	silver quality
C1 segment of cervical spinal cord	UBERON:0006469	37.95	silver quality
hypothalamus	UBERON:0001898	37.79	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	2.61

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 15)

• The ectopic expression of LSINCT5 in gastrointestinal cancer cell lines resulted in an increase in cellular proliferation; conversely, knock down of LSINCT5 significantly inhibited proliferation. (PMID:25526476)
• Circulating CUDR, LSINCT-5 and PTENP1 were identified as potential diagnostic markers for gastric cancer diagnosis. (PMID:25694351)
• high expression levels of BNP promote the apoptosis of myocardial cells through the lncRNA LSINCT5 mediator. (PMID:26323562)
• lncRNA long stress-induced noncoding transcript 5 (LSINCT5) is significantly upregulated in human bladder cancer cell lines and tumor specimens. Mechanistic investigations showed that LSINCT5 could physically interact with NCYM, a de novo gene product from the MYCN cis-antisense RNA and inhibit GSK3beta activity leading to enhanced Wnt/beta-catenin signaling activation and epithelial mesenchymal transition (EMT). (PMID:29772237)
• The expression levels of LSINCT5 was related to the body mass index in women. (PMID:29785740)
• LSINCT5 may possibly contribute to non-small cell lung cancer tumorigenesis by stabilizing the oncogenic factor of HMGA2. (PMID:29883241)
• LSINCT5 interacted with EZH2 to suppress the expression of APC, a negative regulator of the Wnt/beta-catenin pathway. (PMID:30420287)
• LSINCT5 could bind to HMGA2 and decrease proteasome-mediated HMGA2 degradation leading to EMT activation. LSINCT5 also served as a competing endogenous RNA (ceRNA) for miR-4516, resulting in increased STAT3/BclxL expression and attenuated apoptosis. (PMID:30472720)
• study suggests that LSINCT5 exerts oncogenic function in osteosarcoma cells, and may be a potential predictor for clinical outcome in osteosarcoma patients. (PMID:30967495)
• Down-regulation of LSINCT5 represses glioma cells growth and metastasis in vitro likely through targeting miR-451 and thereby inhibiting Rac1-regulated PI3K/AKT, Wnt/beta-catenin and NF-kappaB pathways (PMID:31213092)
• Long noncoding RNA LSINCT5 is upregulated and promotes the progression of esophageal squamous cell carcinoma. (PMID:31298370)
• Effect of long non-coding RNA long stress-induced noncoding transcript 5 on erlotinib resistance to lung cancer cells and the underlying mechanisms.", trans “RNA5. (PMID:33053528)
• LncRNA LSINCT5 drives proliferation and migration of oral squamous cell carcinoma through the miRNA-185-5p/ZNF703 axis. (PMID:33721442)
• LncRNA LSINCT5/miR-222 regulates myocardial ischemiareperfusion injury through PI3K/AKT pathway. (PMID:34184201)
• LSINCT5: A Novel lncRNA in Cancers. (PMID:36734894)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.